GlaxoSmithKline Forced to Pay Over $120 Million in Poligrip Lawsuits

As one of the worlds largest drug manufacturers, GlaxomithKline (GSK) has been forced to continue its relentless defense against numerous Poligrip denture cream lawsuits. Reports continue to surface about consumers claiming to have suffered permanent nerve damage due to the exposure of zinc in GSK denture adhesive products. In fact, GSK has paid at least $120 million to resolve claims that some of its Poligrip products are responsible for severe neurological disorders.

According to recent data accumulated by Bloomberg News, sources estimate that GSK has closed the books on more than 100 lawsuits in the past nine months. In these cases, plaintiffs alleged that the drug maker failed to adequately warn consumers about the potentially dangerous side effects associated with the zinc found in their Poligrip denture adhesive products. As a result, GSK was forced to pay an average compensation of $1 million per settlement. Experts predict that GSK may have paid an excess of more than $120 million in Poligrip denture cream settlements.

In every case aimed at GSK, accusations were made on behalf of individuals who claim to have suffered catastrophic neurological injuries as a result of the manufacturer’s failure to disclose that the denture cream contained zinc. According to the reports, the zinc found in Poligrip may be absorbed into the bloodstream and lead to permanent and debilitating neurological conditions including neuropathy, numbness, tingling, pain, weakness, loss of sensation, loss of balance, paralysis and difficulty breathing.

Any current or future federal lawsuits pertaining to denture cream zinc poisoning has been delegated to Judge Cecilia M. Altnoaga in the U.S. District Court for the Southern District of Florida for pretrial litigation.